AVROBIO(AVRO)
Search documents
AVROBIO(AVRO) - 2023 Q2 - Quarterly Report
2023-08-09 16:00
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38537 AVROBIO, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 81-0710585 (State or other jurisdiction of (I. ...
AVROBIO(AVRO) - 2023 Q1 - Quarterly Report
2023-05-10 16:00
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38537 AVROBIO, INC. (Exact Name of Registrant as Specified in its Charter) Registrant's telephone number, including area code: (6 ...
AVROBIO(AVRO) - 2022 Q4 - Annual Report
2023-03-22 16:00
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-38537 | --- | --- | --- | --- | |-----------------|-------------------------|----------|----------------------------------------| | clas ...
AVROBIO (AVRO) Investor Presentation - Slideshow
2023-03-10 13:42
March 2023 Arianna living with Gaucher disease type 3 1 Disclaimer This presentation has been prepared by AVROBIO, Inc. (“AVROBIO”) clinical trial results, and product approvals; the timing and results of results, such as signals of safety, activity, or durability of effect, for informational purposes only and not for any other purpose. Certain our ongoing preclinical studies; the anticipated benefits of our gene observed from preclinical or clinical trials, will not be replicated or information contained i ...